Replies to post #192209 on Avid Bioservices Inc (CDMO)

[md1225]

We better hear something the first week of October. Bavituximab is the first mab/immunotherapy under CRI's website for lung cancer. Peregrine will be there in NYC a lot of eyes on them.

http://www.cancerresearch.org/cancer-immunotherapy/impacting-all-cancers/lung-cancer